Sticking to the script: Breast cancer patients’ decision making regarding oral endocrine therapy

Abstract

ObjectivesWe sought to understand why some women with early-stage breast cancer decide to forgo or discontinue endocrine therapy (ET), and to identify factors that might lead to greater acceptance of, and long-term adherence to, this treatment. MethodsWe conducted in-depth interviews with N = 53 stage I-III HR+ women who were either non-initiators of ET, initiators who discontinued or initiators who continued with variable daily patterns of adherence. An inductive content analysis was performed to explore the decision-making process of women prescribed ET. ResultsQualitative analyses revealed 55 themes that drove complex decision making. The initiators generally trusted their physicians and did little research before starting the medication. Non-initiators were more suspicious of the medical system, believing that ET presented more risks than benefits. Most discontinuers stopped ET because of side effects. Both non-initiators and discontinuers indicated that push-back from their physicians could have changed their decision. Stories and social support were important in decision making. ConclusionsAlthough ET can significantly reduce the risk of breast cancer recurrence, substantial barriers prevent many women from initiating or continuing it. Practice ImplicationsPhysicians have powerful influence over patients’ decisions to initiate ET and can be important levers for motivating patients to persist.